FMC CORP — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
FMC reported Q2 2026 revenue of $867M (down 17% YoY) with adjusted EBITDA of $153M (down 26% YoY). The company lowered full-year 2026 guidance: revenue to $3.50–$3.70B (down 7% at midpoint), adjusted EBITDA to $620–$680M (down 23%), and adjusted EPS to $1.19–$1.49 (down 55%). Management cited challenging macro conditions, lower pricing (mid-to-high single digits), and 10% volume declines. Concurrently, FMC executed ~$1B in debt-reduction transactions: $252M sale of India commercial business to Crystal Crop Protection, $200M upfront licensing deal with Corteva for rimisoxafen, $114M sale-leaseback of Newark property, and $400M equity investment from Tessenderlo Group.
Why this rating
Major earnings deterioration (55% EPS cut) and strategic restructuring relative to $5.2B market cap. Debt reduction positive; demand collapse and margin pressure concerning.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.